Primary Intraprostatic Synovial Sarcoma.

Primary intraprostatic synovial sarcoma is a rare presentation of an otherwise well-studied disease, and it is one of the few primary sarcomas to occur in the prostate. Ancillary diagnostic techniques including immunohistochemistry and molecular genetics are useful to establish a definitive diagnosis. Despite its unorthodox location, it shares histologic and molecular genetic characteristics with tumors found elsewhere in the body. Most notably, the chromosomal translocation t(X;18)(p11;q11) encodes a chimeric transcription-activating protein, SS18-SSX, which has been identified as the primary driver mutation. The SS18-SSX fusion gene provides a consistent and dependable means of establishing a definitive diagnosis via reverse transcription-polymerase chain reaction or fluorescence in situ hybridization. Recent studies have continued to provide insight into the oncogenesis of this disease. The goal of this review is to elaborate on the clinicopathologic characteristics and underline those techniques that best facilitate the diagnosis of primary intraprostatic synovial sarcoma.

[1]  W. Sexton,et al.  Adult prostate sarcoma: the M. D. Anderson Cancer Center Experience. , 2001, The Journal of urology.

[2]  H. Yoshikawa,et al.  Synovial Sarcoma Is a Stem Cell Malignancy , 2010, Stem cells.

[3]  Qi Zhang,et al.  Primary synovial sarcoma of the prostate metastatic to the liver and lung: a case report , 2014, World Journal of Surgical Oncology.

[4]  S. Suster,et al.  Primary Synovial Sarcomas of the Mediastinum: A Clinicopathologic, Immunohistochemical, and Ultrastructural Study of 15 Cases , 2005, The American journal of surgical pathology.

[5]  L. Pang,et al.  Identification of potential mutations and genomic alterations in the epithelial and spindle cell components of biphasic synovial sarcomas using a human exome SNP chip , 2015, BMC Medical Genomics.

[6]  Xiang Li,et al.  Twenty-five cases of adult prostate sarcoma treated at a high-volume institution from 1989 to 2009. , 2013, Urology.

[7]  A. Folpe,et al.  TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasms , 2009, Modern Pathology.

[8]  Rolph Pfundt,et al.  Next generation sequencing in synovial sarcoma reveals novel gene mutations , 2015, Oncotarget.

[9]  Y. Iwamoto,et al.  Reduced expression of SMARCB1/INI1 protein in synovial sarcoma , 2010, Modern Pathology.

[10]  G. Dumanian,et al.  Synovial sarcoma of the prostate. , 2004, The Journal of urology.

[11]  F. Collin,et al.  Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Wang Zhaoming,et al.  Primary synovial sarcoma of the prostate: report of 2 cases and literature review. , 2008, International journal of surgical pathology.

[13]  M. Ladanyi,et al.  SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. , 1998, The New England journal of medicine.

[14]  G. Crabtree,et al.  Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma , 2013, Cell.

[15]  Y. Kaneko,et al.  Synovial sarcoma of the prostate with t(X;18)(p11.2;q11.2). , 1999, The American journal of surgical pathology.

[16]  Marc Ladanyi,et al.  Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. , 2015, Cancer discovery.

[17]  Y. Chang,et al.  Primary synovial sarcoma of the prostate , 2006, Histopathology.

[18]  P. Russo,et al.  Adult prostate sarcoma: the Memorial Sloan Kettering experience. , 2014, Urology.

[19]  Choung-Soo Kim,et al.  Histologic Variability and Diverse Oncologic Outcomes of Prostate Sarcomas , 2014, Korean journal of urology.